{"schema_version":"secwatch.filing_event.v1","accession":"0001822479-23-000049","form_type":"8-K","ticker":"SHC","cik":"0001822479","company_name":"Sotera Health Co","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.456295+00:00","generated_at":"2026-06-12T09:13:57.748451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sotera Health Q2 net revenue $255M (-4% YoY), net income $24M; cuts full-year outlook","bullets":["Q2 net revenues $255M, down 4% YoY; net income $24M ($0.08 diluted EPS) vs $30M ($0.11) in Q2 2022.","Adjusted EBITDA $128M, down 6% YoY; Adjusted EPS $0.21 vs $0.27 in prior year.","Full-year 2023 guidance revised: net revenue $1.035B-$1.055B, Adjusted EBITDA $520M-$535M.","Decline driven by expected Nordion Cobalt-60 harvest schedule timing.","Total debt $2.3B, net leverage ratio 4.2x as of June 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001822479-23-000049","json":"https://secwatch.observer/filing/0001822479-23-000049.json","markdown":"https://secwatch.observer/filing/0001822479-23-000049.md","text":"https://secwatch.observer/filing/0001822479-23-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822479/000182247923000049/0001822479-23-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822479/000182247923000049/shc-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:13:57.748451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"028f044bd420cba6051684e9f0072740032a263c","claim":"Sotera Health Co reported the quarter ended June 30, 2023 results: revenue $255 million, net income $24 million or $0.08 per diluted share, EPS $0.08 per diluted share. Guidance reaffirmed.","evidence_excerpt":"incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Sotera Health Reports Second-Quarter and First-Half 2023 Results • Q2 2023 net revenues of $255 million decreased 4%, compared to Q2 2022, primarily driven by expected Nordion Cobalt-60 harvest schedule timing • Q2 2023 net income of $24 million or $0.08 per diluted share, compared","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822479/000182247923000049/0001822479-23-000049-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$255 million"},{"label":"Net income","value":"$24 million or $0.08 per diluted share"},{"label":"EPS","value":"$0.08 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}